Unique ID issued by UMIN | UMIN000002249 |
---|---|
Receipt number | R000002754 |
Scientific Title | FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer. |
Date of disclosure of the study information | 2009/07/25 |
Last modified on | 2022/02/02 09:24:54 |
FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.
FDG-PET for prediction of the efficacy of chemoradiotherapy.
FDG-PET for prediction of the efficacy of chemotherapy followed by chemoradiotherapy for Stage II/III esophageal cancer.
FDG-PET for prediction of the efficacy of chemoradiotherapy.
Japan |
Esophageal cancer
Gastroenterology |
Malignancy
NO
To investigate an association between FDG-PET finding during induction chemotherapy and the efficacy of chemoradiation.
Safety,Efficacy
Exploratory
Explanatory
Not applicable
An association between FDG-PET finding during induction chemotherapy and the efficacy of chemoradiotherapy (CR or Non-CR).
An association between FDG-PET finding during induction chemotherapy and overall survival.
An association between FDP-PET finding during induction chemotherapy and disease-free survival.
Safety. Optimal cut off value to predict CR
Adverse event.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Diagnosis
Device,equipment |
FDG-PET was performed before and after inductuion chemotherapy
20 | years-old | <= |
80 | years-old | >= |
Male and Female
(1)Stage II/III (Excluding T4) esophageal cancer.
(2)Inclusion criteria
1)Lesion mainly located in the thoracic esophagus. Histologically proven squamous cell carcinoma.
2)No previous chemotherapy against any cancer.
3)Aged 20 to 80 years old
4)ECOG Performance status 0 or 1.
5)Written informed consent.
6)Adequate organ functions.
1)Esophageal cancer spreading to pharynx or stomach.
2)Simultaneous double cancers.
3)Previous radiotherapy against cancer of thoracic cavity.
4)Uncontrollable complicating disease.
5)Interstitial pneumonia, fibroid lung.
6)History of collagen disease.
7)Psychosis.
8)Active infection which should be treated.
9)HBs antigen positive. HCV positive, TPHA positive, HIV positive
10)Women during pregnancy or breast-feeding. Men expecting to have a child.
30
1st name | Ryu |
Middle name | |
Last name | Ishihara |
Osaka Medical Center for Cancer and Cardiovascular Diseases
Department of Gastrointestinal Oncology
5418567
3-3, Nakamichi 1 chome, Higashinari-ku, Osaka 537-8511
06-6972-1181
ryu1486@gmail.com
1st name | Sachiko |
Middle name | |
Last name | Yamamoto |
Osaka Medical Center for Cancer and Cardiovascular Diseases
Department of Gastrointestinal Oncology
5418567
3-3, Nakamichi 1 chome, Higashinari-ku, Osaka 537-8511
06-6972-1181
yamamoto-sa@mc.pref.osaka.jp
Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka Medical Center for Cancer and Cardiovascular Diseases
Self funding
Japan
N/A
N/A
Osaka International Cancer Institute
3-1-69, Otemae, Chuoku, Osaka
06-6945-1181
rinri01@opho.jp
NO
2009 | Year | 07 | Month | 25 | Day |
Unpublished
Open public recruiting
2009 | Year | 07 | Month | 24 | Day |
2009 | Year | 07 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2018 | Year | 12 | Month | 01 | Day |
2018 | Year | 12 | Month | 01 | Day |
2009 | Year | 07 | Month | 25 | Day |
2022 | Year | 02 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002754